Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LD013 / Nanjing Blue Shield Biotech
NCT05372692: Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer	Completed	N/A	3	RoW	mesothelin-specific chimeric antigen receptor T cell injection, LD013	Weijia Fang, MD, Nanjing Blue Shield Biotech Co.,Ltd	Ovarian Cancer	02/23	02/23